Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887696 | 0.89 | DPP8 (0.38) | RAB9AALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL7729879 | 0.83 | RAB9A (0.35) | RAB9AHTR2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6887473 | 0.80 | RAB9A (0.41) | RAB9AALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL6888050 | 0.70 | DPP8 (0.35) | ALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL6893524 | 0.69 | DPP8 (0.40) | RAB9AALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL6621231 | 0.69 | L3MBTL1 (0.35) | RAB9AALDH1A1MAPTL3MBTL1CYP19A1 | |
| SCHEMBL6772807 | 0.68 | DPP8 (0.42) | RAB9AALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL5233372 | 0.67 | PREP (0.41) | RAB9AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6623459 | 0.66 | DPP8 (0.44) | RAB9AALDH1A1MAPTL3MBTL1HTT | |
| SCHEMBL5233019 | 0.66 | POLB (0.36) | RAB9AALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | RAB9A 1538/4885HTR2A 4579/4885ALDH1A1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.